The Experts below are selected from a list of 270960 Experts worldwide ranked by ideXlab platform
Brian M Grawe - One of the best experts on this subject based on the ideXlab platform.
-
correlation of patient reported outcome measurement inFormation system physical function upper extremity computer adaptive testing with the american shoulder and elbow surgeons shoulder Assessment Form and simple shoulder test in patients with shoulder pain
Arthroscopy, 2018Co-Authors: Chelsea E Minoughan, Adam P Schumaier, John L Fritch, Brian M GraweAbstract:Purpose To evaluate the Patient-Reported Outcome Measurement InFormation System Physical Function Upper Extremity Computer Adaptive Testing (PROMIS PFUE CAT) measurement tool against the already validated American Shoulder and Elbow Surgeons Shoulder Assessment Form (ASES) and the Simple Shoulder Test (SST) in patients presenting with shoulder pain and determine the responder burden for each of the 3 surveys. Methods Ninety patients presenting with shoulder pain were asked to fill out the ASES, SST, and PROMIS PFUE CAT. The time for completion of each survey was measured to determine responder burden, and the Pearson correlation between the 3 instruments was defined as excellent (r > 0.7), excellent-good (0.61 ≤ r ≤ 0.7), good (0.31 ≤ r ≤ 0.6), and poor (0.2 ≤ r ≤ 0.3). Results The PROMIS PFUE CAT showed an excellent correlation with the SST (r = 0.82, P Conclusions The PROMIS PFUE CAT showed an excellent correlation with the previously validated ASES and SST in patients with shoulder pain. The time saving of the PROMIS PFUE CAT was found to be smaller than that of the ASES and SST but shows that moving forward, using the PROMIS PFUE CAT would not place any additional burden on the patient filling out the survey. The lack of ceiling or floor effects with the PROMIS PFUE CAT indicates its ability to differentiate both high and low functioning patients. All of these findings indicate that the PROMIS PFUE CAT is an adequate tool for the evaluation of patients with shoulder pain and should be used in these patients going forward. Level of evidence Level II, diagnostic study.
-
correlation of promis physical function upper extremity computer adaptive test with american shoulder and elbow surgeons shoulder Assessment Form and simple shoulder test in patients with shoulder arthritis
Journal of Shoulder and Elbow Surgery, 2017Co-Authors: Chelsea E Minoughan, Adam P Schumaier, John L Fritch, Brian M GraweAbstract:Background The purpose of this study was to evaluate the Patient-Reported Outcomes Measurement InFormative System Physical Function Upper Extremity Computer Adaptive Test (PROMIS PFUE CAT) measurement tool against the already validated American Shoulder and Elbow Surgeons (ASES) shoulder Assessment Form and the Simple Shoulder Test (SST) in patients with shoulder arthritis. Methods Fifty-two patients with the primary diagnosis of shoulder arthritis were asked to fill out the ASES, SST, and PROMIS PFUE CAT. The time for completion of each survey was measured to determine responder burden, and correlation between the 3 instruments was defined as excellent (>0.7), strong-moderate (0.61-0.7), moderate (0.31-0.6), and poor (0.2-0.3). Results The PROMIS PFUE CAT showed a strong-moderate correlation with the SST (r = 0.64; P Conclusion In patients with shoulder arthritis, The PROMIS PFUE CAT demonstrated strong-moderate correlation with the SST and moderate correlation with the ASES. The time savings of the PROMIS PFUE CAT were small compared with the ASES and SST but demonstrate that moving forward, using the PROMIS PFUE CAT would not place any additional burden on the patient filling out the survey. These findings indicate that the PROMIS PFUE CAT is an appropriate measurement tool for patients with shoulder arthritis.
-
correlation of promis physical function upper extremity computer adaptive test with american shoulder and elbow surgeons shoulder Assessment Form and simple shoulder test in patients with shoulder arthritis
Journal of Shoulder and Elbow Surgery, 2017Co-Authors: Chelsea E Minoughan, Adam P Schumaier, John L Fritch, Brian M GraweAbstract:Background The purpose of this study was to evaluate the Patient-Reported Outcomes Measurement InFormative System Physical Function Upper Extremity Computer Adaptive Test (PROMIS PFUE CAT) measurement tool against the already validated American Shoulder and Elbow Surgeons (ASES) shoulder Assessment Form and the Simple Shoulder Test (SST) in patients with shoulder arthritis. Methods Fifty-two patients with the primary diagnosis of shoulder arthritis were asked to fill out the ASES, SST, and PROMIS PFUE CAT. The time for completion of each survey was measured to determine responder burden, and correlation between the 3 instruments was defined as excellent (>0.7), strong-moderate (0.61-0.7), moderate (0.31-0.6), and poor (0.2-0.3). Results The PROMIS PFUE CAT showed a strong-moderate correlation with the SST (r = 0.64; P Conclusion In patients with shoulder arthritis, The PROMIS PFUE CAT demonstrated strong-moderate correlation with the SST and moderate correlation with the ASES. The time savings of the PROMIS PFUE CAT were small compared with the ASES and SST but demonstrate that moving forward, using the PROMIS PFUE CAT would not place any additional burden on the patient filling out the survey. These findings indicate that the PROMIS PFUE CAT is an appropriate measurement tool for patients with shoulder arthritis.
Elizabeth A Rider - One of the best experts on this subject based on the ideXlab platform.
-
the reliability of a modified kalamazoo consensus statement checklist for assessing the communication skills of multidisciplinary clinicians in the simulated environment
Patient Education and Counseling, 2014Co-Authors: Eleanor B Peterson, Elizabeth A Rider, Aaron W CalhounAbstract:Abstract Objective With increased recognition of the importance of sound communication skills and communication skills education, reliable Assessment tools are essential. This study reports on the psychometric properties of an Assessment tool based on the Kalamazoo Consensus Statement Essential Elements Communication Checklist. Methods The Gap-Kalamazoo Communication Skills Assessment Form (GKCSAF), a modified version of an existing communication skills Assessment tool, the Kalamazoo Essential Elements Communication Checklist-Adapted, was used to assess learners in a multidisciplinary, simulation-based communication skills educational program using multiple raters. 118 simulated conversations were available for analysis. Internal consistency and inter-rater reliability were determined by calculating a Cronbach's alpha score and intra-class correlation coefficients (ICC), respectively. Results The GKCSAF demonstrated high internal consistency with a Cronbach's alpha score of 0.844 (faculty raters) and 0.880 (peer observer raters), and high inter-rater reliability with an ICC of 0.830 (faculty raters) and 0.89 (peer observer raters). Conclusion The Gap-Kalamazoo Communication Skills Assessment Form is a reliable method of assessing the communication skills of multidisciplinary learners using multi-rater methods within the learning environment. Practice implications The Gap-Kalamazoo Communication Skills Assessment Form can be used by educational programs that wish to implement a reliable Assessment and feedback system for a variety of learners.
-
the reliability of a modified kalamazoo consensus statement checklist for assessing the communication skills of multidisciplinary clinicians in the simulated environment
Patient Education and Counseling, 2014Co-Authors: Eleanor B Peterson, Elizabeth A Rider, Aaron W CalhounAbstract:Abstract Objective With increased recognition of the importance of sound communication skills and communication skills education, reliable Assessment tools are essential. This study reports on the psychometric properties of an Assessment tool based on the Kalamazoo Consensus Statement Essential Elements Communication Checklist. Methods The Gap-Kalamazoo Communication Skills Assessment Form (GKCSAF), a modified version of an existing communication skills Assessment tool, the Kalamazoo Essential Elements Communication Checklist-Adapted, was used to assess learners in a multidisciplinary, simulation-based communication skills educational program using multiple raters. 118 simulated conversations were available for analysis. Internal consistency and inter-rater reliability were determined by calculating a Cronbach's alpha score and intra-class correlation coefficients (ICC), respectively. Results The GKCSAF demonstrated high internal consistency with a Cronbach's alpha score of 0.844 (faculty raters) and 0.880 (peer observer raters), and high inter-rater reliability with an ICC of 0.830 (faculty raters) and 0.89 (peer observer raters). Conclusion The Gap-Kalamazoo Communication Skills Assessment Form is a reliable method of assessing the communication skills of multidisciplinary learners using multi-rater methods within the learning environment. Practice implications The Gap-Kalamazoo Communication Skills Assessment Form can be used by educational programs that wish to implement a reliable Assessment and feedback system for a variety of learners.
Chelsea E Minoughan - One of the best experts on this subject based on the ideXlab platform.
-
correlation of patient reported outcome measurement inFormation system physical function upper extremity computer adaptive testing with the american shoulder and elbow surgeons shoulder Assessment Form and simple shoulder test in patients with shoulder pain
Arthroscopy, 2018Co-Authors: Chelsea E Minoughan, Adam P Schumaier, John L Fritch, Brian M GraweAbstract:Purpose To evaluate the Patient-Reported Outcome Measurement InFormation System Physical Function Upper Extremity Computer Adaptive Testing (PROMIS PFUE CAT) measurement tool against the already validated American Shoulder and Elbow Surgeons Shoulder Assessment Form (ASES) and the Simple Shoulder Test (SST) in patients presenting with shoulder pain and determine the responder burden for each of the 3 surveys. Methods Ninety patients presenting with shoulder pain were asked to fill out the ASES, SST, and PROMIS PFUE CAT. The time for completion of each survey was measured to determine responder burden, and the Pearson correlation between the 3 instruments was defined as excellent (r > 0.7), excellent-good (0.61 ≤ r ≤ 0.7), good (0.31 ≤ r ≤ 0.6), and poor (0.2 ≤ r ≤ 0.3). Results The PROMIS PFUE CAT showed an excellent correlation with the SST (r = 0.82, P Conclusions The PROMIS PFUE CAT showed an excellent correlation with the previously validated ASES and SST in patients with shoulder pain. The time saving of the PROMIS PFUE CAT was found to be smaller than that of the ASES and SST but shows that moving forward, using the PROMIS PFUE CAT would not place any additional burden on the patient filling out the survey. The lack of ceiling or floor effects with the PROMIS PFUE CAT indicates its ability to differentiate both high and low functioning patients. All of these findings indicate that the PROMIS PFUE CAT is an adequate tool for the evaluation of patients with shoulder pain and should be used in these patients going forward. Level of evidence Level II, diagnostic study.
-
correlation of promis physical function upper extremity computer adaptive test with american shoulder and elbow surgeons shoulder Assessment Form and simple shoulder test in patients with shoulder arthritis
Journal of Shoulder and Elbow Surgery, 2017Co-Authors: Chelsea E Minoughan, Adam P Schumaier, John L Fritch, Brian M GraweAbstract:Background The purpose of this study was to evaluate the Patient-Reported Outcomes Measurement InFormative System Physical Function Upper Extremity Computer Adaptive Test (PROMIS PFUE CAT) measurement tool against the already validated American Shoulder and Elbow Surgeons (ASES) shoulder Assessment Form and the Simple Shoulder Test (SST) in patients with shoulder arthritis. Methods Fifty-two patients with the primary diagnosis of shoulder arthritis were asked to fill out the ASES, SST, and PROMIS PFUE CAT. The time for completion of each survey was measured to determine responder burden, and correlation between the 3 instruments was defined as excellent (>0.7), strong-moderate (0.61-0.7), moderate (0.31-0.6), and poor (0.2-0.3). Results The PROMIS PFUE CAT showed a strong-moderate correlation with the SST (r = 0.64; P Conclusion In patients with shoulder arthritis, The PROMIS PFUE CAT demonstrated strong-moderate correlation with the SST and moderate correlation with the ASES. The time savings of the PROMIS PFUE CAT were small compared with the ASES and SST but demonstrate that moving forward, using the PROMIS PFUE CAT would not place any additional burden on the patient filling out the survey. These findings indicate that the PROMIS PFUE CAT is an appropriate measurement tool for patients with shoulder arthritis.
-
correlation of promis physical function upper extremity computer adaptive test with american shoulder and elbow surgeons shoulder Assessment Form and simple shoulder test in patients with shoulder arthritis
Journal of Shoulder and Elbow Surgery, 2017Co-Authors: Chelsea E Minoughan, Adam P Schumaier, John L Fritch, Brian M GraweAbstract:Background The purpose of this study was to evaluate the Patient-Reported Outcomes Measurement InFormative System Physical Function Upper Extremity Computer Adaptive Test (PROMIS PFUE CAT) measurement tool against the already validated American Shoulder and Elbow Surgeons (ASES) shoulder Assessment Form and the Simple Shoulder Test (SST) in patients with shoulder arthritis. Methods Fifty-two patients with the primary diagnosis of shoulder arthritis were asked to fill out the ASES, SST, and PROMIS PFUE CAT. The time for completion of each survey was measured to determine responder burden, and correlation between the 3 instruments was defined as excellent (>0.7), strong-moderate (0.61-0.7), moderate (0.31-0.6), and poor (0.2-0.3). Results The PROMIS PFUE CAT showed a strong-moderate correlation with the SST (r = 0.64; P Conclusion In patients with shoulder arthritis, The PROMIS PFUE CAT demonstrated strong-moderate correlation with the SST and moderate correlation with the ASES. The time savings of the PROMIS PFUE CAT were small compared with the ASES and SST but demonstrate that moving forward, using the PROMIS PFUE CAT would not place any additional burden on the patient filling out the survey. These findings indicate that the PROMIS PFUE CAT is an appropriate measurement tool for patients with shoulder arthritis.
Ruben A Mesa - One of the best experts on this subject based on the ideXlab platform.
-
revised response criteria for myelofibrosis international working group myeloproliferative neoplasms research and treatment iwg mrt and european leukemianet eln consensus report
Blood, 2013Co-Authors: Ayalew Tefferi, Francisco Cervantes, Ruben A Mesa, Francesco Passamonti, Srdan Verstovsek, Alessandro M Vannucchi, Jason Gotlib, Brigitte Dupriez, Animesh Pardanani, Claire N HarrisonAbstract:The current document is a revision of the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria for treatment response in myelofibrosis (MF) and represents a collaborative effort by the IWG-MRT and the European LeukemiaNet to objectively assess the value of new drugs in inducing morphologic remission or improvement in MF-associated symptomatic burden (MF-SB). Some of the changes in the current revision include stricter definitions of red cell transfusion dependency and independency and consideration of the Myeloproliferative Neoplasm Symptom Assessment Form as a tool to quantify meaningful changes in disease-related symptoms. Six response categories are listed: complete remission (CR) and partial remission signify treatment effects that are consistent with disease modification, whereas drug-induced improvements in MF-SB were annotated as clinical improvement, anemia response, spleen response, or symptoms response. Additional criteria are provided for progressive disease, stable disease, and relapse. The document also includes recommendations for assessing cytogenetic and molecular remissions, without mandating their inclusion for CR assignment.
-
revised response criteria for polycythemia vera and essential thrombocythemia an eln and iwg mrt consensus project
Blood, 2013Co-Authors: G Barosi, Ruben A Mesa, Francesco Passamonti, Alessandro M Vannucchi, Claire N Harrison, Jean-jacques Kiladjian, Guido Finazzi, Eva Lengfelder, Mary Frances Mcmullin, Carlos BessesAbstract:Standardized response criteria to interpret and compare clinical trials are needed for approval of new therapeutic agents by regulatory agencies. The European LeukemiaNet (ELN) response criteria for essential thrombocythemia (ET) and polycythemia vera (PV) issued in 2009 have been widely adopted as end points in a number of recent clinical trials. However, evidence exists that they do not predict response or provide clinically relevant measures of benefit for the patients. This article presents revised recommendations for assessing response in ET and PV provided by a working group established by ELN and International Working Group-Myeloproliferative Neoplasms Research and Treatment. New definitions of complete and partial remission incorporate clinical, hematological, and histological response Assessments that include a standardized symptom Assessment Form and consider absence of disease progression and vascular events. We anticipate that these criteria will be adopted widely to facilitate the development of new and more effective therapies for ET and PV.
-
effect of ruxolitinib therapy on myelofibrosis related symptoms and other patient reported outcomes in comfort i a randomized double blind placebo controlled trial
Journal of Clinical Oncology, 2013Co-Authors: Ruben A Mesa, Jason Gotlib, Vikas A Gupta, John Catalano, Michael W Deininger, Alan L Shields, Carole B Miller, Richard T Silver, Moshe TalpazAbstract:Purpose To assess the effects of ruxolitinib on symptom burden and quality of life (QoL) and to evaluate the ability of the modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 to measure meaningful changes in myelofibrosis-related symptoms in patients with myelofibrosis. Patients and Methods COMFORT-I (Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment–I) is a double-blind, placebo-controlled phase III study evaluating ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis. Exploratory analyses were conducted on the following patient-reported outcomes (PROs) Assessments: modified MFSAF v2.0 (individual symptoms and Total Symptom Score [TSS]), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), Patient Reported Outcomes Measurement InFormation System (PROMIS) Fatigue Scale, and Patient Global Impression of Change (PGIC). Results Patients receiving ruxolitinib experienced improvements in individual myelofibro...
-
evaluating the serial use of the myelofibrosis symptom Assessment Form for measuring symptomatic improvement perFormance in 87 myelofibrosis patients on a jak1 and jak2 inhibitor incb018424 clinical trial
Cancer, 2011Co-Authors: Ruben A Mesa, Ayalew Tefferi, Amylou C Dueck, Hagop M Kantarjian, Richard Levy, Kris Vaddi, Susan Ericksonviitanen, Deborah A Thomas, Jorge E Cortes, Gautam BorthakurAbstract:Myelofibrosis (MF) is a myeloproliferative neoplasm that is characterized by a series of consequences from the clonal disease.1 Included among the consequences of MF are the development of ineffective hematopoiesis (and thus potentially anemia and other cytopenias), leukoerythroblastosis, splenomegaly through perhaps a variety of mechanisms including (but not limited to) ineffective hematopoiesis and splenic sequestration of immature myeloid cells, significant constitutional symptoms (night sweats, fevers, weight loss), pruritus, risk of blastic transFormation, and premature death.2 We have previously demonstrated that the symptomatic burden among patients with MF is significant both from directly observable effects of disease (ie, from anemia and/or splenomegaly) and by self-reported outcomes from MF patients for less quantifiable symptoms such as fatigue, night sweats, and pruritus.3 We have also reported that the prevalence of these symptoms is relatively uniForm across the 3 main subtypes of MF (namely, primary MF, post-polycythemia vera MF [post-PV MF], and post-essential thrombocythemia MF [post-ET MF]).4 In addition, the presence of significant constitutional symptoms is not only bothersome for the individual patient, but has been found to be prognostically detrimental and is included as an adverse prognostic factor in the International Working Group for Myelofibrosis Research and Treatment prognostic score for MF.5 Historically, therapies for MF have been largely palliative, with very limited ability to significantly impact the symptomatic burden of patients afflicted with the disease. However, the discovery of the JAK2-V617F mutation in 20056 (and subsequent discovery of related myeloproliferative neoplasm-associated mutations7,8) has ushered in an era of targeted therapeutic approaches for MF including JAK inhibitors,9 which down-modulate the dysregulated activity of JAKs that is characteristic in the myeloproliferative neoplasms. Initial results of these targeted trials demonstrated a profound ability of these medications to decrease MF-associated splenomegaly and symptoms.10,11 The difficulty was that no current instrument of patient-reported outcomes adequately and concisely assessed the spectrum of MF-associated symptoms. Therefore, we developed, and validated in a single time point validation study, the Myelofibrosis Symptom Assessment Form.4 This instrument captured the spectrum of MF-associated constitutional symptoms (fatigue, night sweats, fevers, pruritus, weight loss) and splenomegaly-associated symptoms (abdominal pain, early satiety, mechanical effects from the spleen). This prior validation of the Myelofibrosis Symptom Assessment Form used a series of established instruments of patient-reported outcomes to validate the questions and results obtained from the Myelofibrosis Symptom Assessment Form. In addition, a separate question is asked relating to an overall Assessment of quality of life. We sought to evaluate the use of the Myelofibrosis Symptom Assessment Form for measurement of baseline symptoms and sensitivity to detect changes when used serially in clinical trials. Therefore, we used the Myelofibrosis Symptom Assessment Form in serial administrations in conjunction with the largest phase 2 trial ever conducted for that disorder, the open label phase 2 trial of the selective JAK1 and JAK2 inhibitor INCB018424 (Trial 251).10
-
validation of the serial use of the myelofibrosis symptom Assessment Form mf saf for measuring symptomatic improvement perFormance in 86 myelofibrosis patients on incb018424 clinical trial
Blood, 2009Co-Authors: Ruben A Mesa, Ayalew Tefferi, Hagop M Kantarjian, Richard Levy, Kris Vaddi, Susan Ericksonviitanen, Deborah A Thomas, Gautam Borthakur, Jorge Cortesfranco, Animesh PardananiAbstract:Abstract 3917 Poster Board III-853 Background Patients with Myelofibrosis (MF) suffer from significant fatigue, constitutional symptoms and splenomegaly (Mesa et. al. Cancer 2007) not improved by current therapy. The MF-SAF is a 19 item self administered instrument specific to MF associated symptoms previously validated for use at a single time point (Mesa et. al. Leukemia Research 2009). We sought to assess the perFormance characteristics of the MF-SAF when administered sequentially in the context of a prospective clinical trial. Methods Sequential MF patients enrolled in the prospective, uncontrolled Phase II, trial were given a 15 item modified MF-SAF to complete at enrollment, and after 15 days, 1 month, 2 months, 3 months and every 3 months thereafter. The MF-SAF was scored as previously published on a 0 (absent) to 10 (maximal) scale. Cross validation of serial change in MF-SAF scores was undertaken by comparison to objective measurements made as part of the therapeutic drug trial. Results Patients Eighty six MF patients were enrolled and had 2 or more MF-SAF instruments completed to allow for sequential analysis. Patients were of a median age (65 years), gender distribution (35 % females), and disease subtype (53 % PMF) typical for a clinical trial in MF. Baseline MF-SAF Responses: Baseline Assessment of the most frequent MF abnormalities reported by patients completing the MF-SAF (see [Table 1][1]) confirmed the wide prevalence of MF associated symptoms, and their significant severity. General fatigue was the most frequent symptom cited (91%), while cough was the least frequently observed symptom (44%). 95% of patients had at least 2 symptoms present on the MF-SAF. Serial MF-SAF Changes in Response to Therapy Therapy with INCB018424 resulted in a significant and rapid reduction in MF associated symptoms with 46% to 85% of patients experiencing improvement in a given symptom. The greatest improvements in MFSAF score improvements were reported by patients experiencing abdominal discomfort, night sweats, pruritus and fever (see [Table 1][1]), and corresponded to significant improvements in the individual MF symptom scales as well as the patient's overall Assessment of quality of life (QOL). Correlation of MF-SAF to Objective Changes during INCB018424 Therapy Objective measurements obtained on the INCB018424 trial included MRI measurements of splenic reduction, the six minute walk test (6MWT) for inactivity, and serial weights. Reduction in spleen size (by ≥ 35% by volume or ≥ 50% by palpable length) corresponded to improvement in MF-SAF scores of abdominal discomfort and fatigue (50% of patients, median score decrease of -1.2, and -1.8, respectively). Improvement in the 6MWT by > 50 meters was associated with a 2-fold greater improvement in inactivity score on the MF-SAF compared to subjects who improved 6MWT perFormance by <50 meters. Finally, improvements in weight loss and fever were corroborated by objective measurements made at physician visits on the trial. Conclusions The MF-SAF is a brief, easily self administered, MF specific instrument which was successfully administered sequentially in the conduct of a large Phase II clinical trial. The significant symptomatic improvements reported by patients in the open label trial of INCB018424 corresponded to both improvements in symptom specific scores on the MF-SAF and objective measurements. Further validation of the MF-SAF will be possible by inclusion in upcoming randomized placebo controlled trials in MF patients. Parallel trials perFormed in MF patients should consider use of this instrument to allow for comparisons. | | General Fatigue* | Abdom Pain/ Discomfort | Night Sweats | Pruritus | Bone/Muscle Pain | Fever | Cough | Appetite (wt gain or loss) | Ability to move/walk | QOL | |:--------------------------------------------- | ---------------- | ---------------------- | ------------ | -------- | ---------------- | ----- | ----- | -------------------------- | -------------------- | ---- | | N = | 86 | 86 | 85 | 86 | 84 | 86 | 86 | 86 | 86 | 86 | | % with baseline score of > 1 | 91% | 76% | 54% | 45% | 65% | 54% | 44% | 74% | 83% | 91% | | Median Baseline Score | 4.0 | 3.0 | 4.0 | 2.0 | 3.0 | 2.0 | 2.0 | 2.5 | 3.0 | 4.0 | | % Improved | 53% | 66% | 83% | 85% | 46% | 77% | 76% | 61% | 54% | 50% | | Median Score at 6 Months | 2.0 | 1.0 | | | 2.0 | | | 1.0 | 2.0 | 2.0 | | Median Score change from baseline at 6 months | -1.0 | -2.0 | -2.0 | -1.0 | | -2.0 | -1.0 | -1.0 | -1.0 | -1.0 | Table 1 Baseline and Serial change in Myelofibrosis Symptoms in 86 Patients Taking INCB018424 Disclosures: Levy: Incyte Corporation: Employment, Equity Ownership. Vaddi: Incyte Corporation: Employment, Equity Ownership. Erickson-Viitanen: Incyte Corporation: Employment, Equity Ownership. Verstovsek: Incyte: Research Funding. [1]: #T1
Adam P Schumaier - One of the best experts on this subject based on the ideXlab platform.
-
correlation of patient reported outcome measurement inFormation system physical function upper extremity computer adaptive testing with the american shoulder and elbow surgeons shoulder Assessment Form and simple shoulder test in patients with shoulder pain
Arthroscopy, 2018Co-Authors: Chelsea E Minoughan, Adam P Schumaier, John L Fritch, Brian M GraweAbstract:Purpose To evaluate the Patient-Reported Outcome Measurement InFormation System Physical Function Upper Extremity Computer Adaptive Testing (PROMIS PFUE CAT) measurement tool against the already validated American Shoulder and Elbow Surgeons Shoulder Assessment Form (ASES) and the Simple Shoulder Test (SST) in patients presenting with shoulder pain and determine the responder burden for each of the 3 surveys. Methods Ninety patients presenting with shoulder pain were asked to fill out the ASES, SST, and PROMIS PFUE CAT. The time for completion of each survey was measured to determine responder burden, and the Pearson correlation between the 3 instruments was defined as excellent (r > 0.7), excellent-good (0.61 ≤ r ≤ 0.7), good (0.31 ≤ r ≤ 0.6), and poor (0.2 ≤ r ≤ 0.3). Results The PROMIS PFUE CAT showed an excellent correlation with the SST (r = 0.82, P Conclusions The PROMIS PFUE CAT showed an excellent correlation with the previously validated ASES and SST in patients with shoulder pain. The time saving of the PROMIS PFUE CAT was found to be smaller than that of the ASES and SST but shows that moving forward, using the PROMIS PFUE CAT would not place any additional burden on the patient filling out the survey. The lack of ceiling or floor effects with the PROMIS PFUE CAT indicates its ability to differentiate both high and low functioning patients. All of these findings indicate that the PROMIS PFUE CAT is an adequate tool for the evaluation of patients with shoulder pain and should be used in these patients going forward. Level of evidence Level II, diagnostic study.
-
correlation of promis physical function upper extremity computer adaptive test with american shoulder and elbow surgeons shoulder Assessment Form and simple shoulder test in patients with shoulder arthritis
Journal of Shoulder and Elbow Surgery, 2017Co-Authors: Chelsea E Minoughan, Adam P Schumaier, John L Fritch, Brian M GraweAbstract:Background The purpose of this study was to evaluate the Patient-Reported Outcomes Measurement InFormative System Physical Function Upper Extremity Computer Adaptive Test (PROMIS PFUE CAT) measurement tool against the already validated American Shoulder and Elbow Surgeons (ASES) shoulder Assessment Form and the Simple Shoulder Test (SST) in patients with shoulder arthritis. Methods Fifty-two patients with the primary diagnosis of shoulder arthritis were asked to fill out the ASES, SST, and PROMIS PFUE CAT. The time for completion of each survey was measured to determine responder burden, and correlation between the 3 instruments was defined as excellent (>0.7), strong-moderate (0.61-0.7), moderate (0.31-0.6), and poor (0.2-0.3). Results The PROMIS PFUE CAT showed a strong-moderate correlation with the SST (r = 0.64; P Conclusion In patients with shoulder arthritis, The PROMIS PFUE CAT demonstrated strong-moderate correlation with the SST and moderate correlation with the ASES. The time savings of the PROMIS PFUE CAT were small compared with the ASES and SST but demonstrate that moving forward, using the PROMIS PFUE CAT would not place any additional burden on the patient filling out the survey. These findings indicate that the PROMIS PFUE CAT is an appropriate measurement tool for patients with shoulder arthritis.
-
correlation of promis physical function upper extremity computer adaptive test with american shoulder and elbow surgeons shoulder Assessment Form and simple shoulder test in patients with shoulder arthritis
Journal of Shoulder and Elbow Surgery, 2017Co-Authors: Chelsea E Minoughan, Adam P Schumaier, John L Fritch, Brian M GraweAbstract:Background The purpose of this study was to evaluate the Patient-Reported Outcomes Measurement InFormative System Physical Function Upper Extremity Computer Adaptive Test (PROMIS PFUE CAT) measurement tool against the already validated American Shoulder and Elbow Surgeons (ASES) shoulder Assessment Form and the Simple Shoulder Test (SST) in patients with shoulder arthritis. Methods Fifty-two patients with the primary diagnosis of shoulder arthritis were asked to fill out the ASES, SST, and PROMIS PFUE CAT. The time for completion of each survey was measured to determine responder burden, and correlation between the 3 instruments was defined as excellent (>0.7), strong-moderate (0.61-0.7), moderate (0.31-0.6), and poor (0.2-0.3). Results The PROMIS PFUE CAT showed a strong-moderate correlation with the SST (r = 0.64; P Conclusion In patients with shoulder arthritis, The PROMIS PFUE CAT demonstrated strong-moderate correlation with the SST and moderate correlation with the ASES. The time savings of the PROMIS PFUE CAT were small compared with the ASES and SST but demonstrate that moving forward, using the PROMIS PFUE CAT would not place any additional burden on the patient filling out the survey. These findings indicate that the PROMIS PFUE CAT is an appropriate measurement tool for patients with shoulder arthritis.
